98 related articles for article (PubMed ID: 22199309)
1. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers.
Jansen FH; Adoubi I; J C KC; DE Cnodder T; Jansen N; Tschulakow A; Efferth T
Anticancer Res; 2011 Dec; 31(12):4417-22. PubMed ID: 22199309
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53, Ki-67, and CD31 in the vaginal margins of radical hysterectomy in patients with stage IB carcinoma of the cervix.
Silva-Filho AL; Traiman P; Triginelli SA; Reis FM; Pedrosa MS; Miranda D; Abreu ES; Macarenco RS; Cunha-Melo JR
Gynecol Oncol; 2004 Dec; 95(3):646-54. PubMed ID: 15581977
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of Ki-67, CD31 and epidermal growth factor receptor expression in basal cell carcinoma.
Yerebakan O; Ciftçioglu MA; Akkaya BK; Yilmaz E
J Dermatol; 2003 Jan; 30(1):33-41. PubMed ID: 12598707
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
7. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
9. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Sotoca A; Pérez-Ruiz E; Lanzós E
Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer.
Ferrandina G; Ranelletti FO; Larocca LM; Maggiano N; Fruscella E; Legge F; Santeusanio G; Bombonati A; Mancuso S; Scambia G
Clin Cancer Res; 2001 Sep; 7(9):2656-61. PubMed ID: 11555576
[TBL] [Abstract][Full Text] [Related]
11. [Ki-67 expression as a predictor of the effectiveness of radiotherapy and of outcome in locally advanced squamous cell carcinoma of the uterine cervix (immunohistochemical study)].
Kuznetsova ME; Pozharisskiĭ KM; Vinokurova VL; Zharinov GM; Neklasova NIu
Vopr Onkol; 2007; 53(2):175-80. PubMed ID: 17663171
[TBL] [Abstract][Full Text] [Related]
12. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
13. EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.
Meert AP; Martin B; Verdebout JM; Feoli F; Mascaux C; Ninane V; Sculier JP
Anticancer Res; 2006; 26(1A):135-8. PubMed ID: 16475689
[TBL] [Abstract][Full Text] [Related]
14. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Hironaka S; Hasebe T; Kamijo T; Ohtsu A; Boku N; Yoshida S; Saitoh H; Ochiai A
Clin Cancer Res; 2002 Jan; 8(1):124-30. PubMed ID: 11801548
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
[TBL] [Abstract][Full Text] [Related]
16. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
17. Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma.
Katori H; Nozawa A; Tsukuda M
Acta Otolaryngol; 2007 Nov; 127(11):1207-13. PubMed ID: 17851915
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
[TBL] [Abstract][Full Text] [Related]
19. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance.
Kohler M; Janz I; Wintzer HO; Wagner E; Bauknecht T
Anticancer Res; 1989; 9(6):1537-47. PubMed ID: 2697181
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Decensi A; Puntoni M; Pruneri G; Guerrieri-Gonzaga A; Lazzeroni M; Serrano D; Macis D; Johansson H; Pala O; Luini A; Veronesi P; Galimberti V; Dotti MC; Viale G; Bonanni B
Cancer Prev Res (Phila); 2011 Aug; 4(8):1181-9. PubMed ID: 21685235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
